The FDA established an internal council to review the post-market safety of vaccines, gene therapies and other biologic products. The council takes effect November 19 and will advise on safety concerns, labeling changes, risk-management measures and potential market withdrawals.
The FDA established the CBER Safety Council within its Center for Biologics Evaluation and Research, separating post-market safety reviews from the offices responsible for approving biologic products. It reports directly to the center’s director and supersedes the existing Safety Working Group.
The council will review safety signals, conduct benefit-risk assessments and recommend regulatory actions as warranted. Its mandate includes emerging safety concerns, potential labeling changes, risk-management measures, post-market studies and advice on potential market withdrawals.
The council will coordinate with the Centers for Disease Control and Prevention and the National Institutes of Health, and draw on VAERS and the FDA Sentinel program. The agency said further details on the council’s structure and membership will be released later.